Approval · Notice of Compliance 16197 · 2014
VAN-GABAPENTIN: Notice of Compliance 16197
Issued October 17, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16197
- Date
- October 17, 2014
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN (Pfizer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-GABAPENTIN | 02431408 | Cancelled Post Market |
| VAN-GABAPENTIN | 02431416 | Cancelled Post Market |
| VAN-GABAPENTIN | 02431424 | Cancelled Post Market |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP